iBio, Inc. (IBIO)
IBIONASDAQ-CMBiotechnology: Pharmaceutical Preparations
$0.8186
+0.1036 (+14.49%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $51.12m
- P/E
- –
- EPS, last 4 quarters
- $-0.3100
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.6859 to $3.82
- Average volume
- 673.5k
- Previous close
- $0.7150
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $6.00, +633.0% from here
Earnings
next estimate $-0.0600Next report Nov 11, 2026
Sep 2025
-57.1%
Dec 2025
-12.5%
Mar 2026
-16.7%
Jun 2026
+42.9%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $100.0k | – | – | – |
| Gross profit | $100.0k | – | – | – |
| Operating income | -$5.95m | -$9.45m | -$8.37m | -$11.38m |
| Net income | -$5.72m | -$8.99m | -$7.73m | -$10.60m |
News
8 latest- IBio Reprots Preclinical Data Showing Potential For Muscle Preservation With IBIO-610 RTTNews · Oct 13, 2026
- HC Wainwright & Co. initiates coverage of iBio with a Buy ratingFintel · Sep 17, 2026
- IBio Names Molly Carr As Chief Medical Officer RTTNews · Aug 4, 2026
- Weekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goal RTTNews · Jul 2, 2026
- IBio's IBIO-610 Achieves Near-Complete Activin E Inhibition In Obese Primate Study RTTNews · Jul 1, 2026
- iBio (IBIO) Price Target Increased by 18.73% to 5.47Fintel · Mar 27, 2026
- Jones Trading Initiates Coverage of iBio (IBIO) with Buy RecommendationFintel · Mar 3, 2026
- iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseZacks · Feb 2, 2026
The company
iBio (Nasdaq: IBIO) is a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other hard-to-treat diseases. Combining advanced antibody engineering with AI-driven discovery, iBio is advancing a differentiated pipeline designed to deliver sustained therapeutic effects and address significant unmet medical needs. iBio's mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- ibioinc.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.